As with most malignancies, there is still no effective treatment for glioma. The main dilemmas are: surgery is difficult for total resection, radiotherapy is not highly sensitive, no effective targeted drugs have been identified, and gene therapy and immunotherapy are still in the experimental stage. Early screening to detect tumors and treating them in the nascent stage can significantly increase the probability of curing glioma. Because there are no established tumor markers for glioma, early screening for glioma relies more on cranial MRI scans. Although there is a trend of increasing incidence of glioma in recent years, due to the low incidence of glioma, about 7/100,000; many patients and families have never heard of glioma before the diagnosis. Therefore, glioma science is important, and cranial MRI screening is recommended to detect early gliomas. Gliomas detected by screening are generally small, located in non-functional areas, and are expected to be cured by extended resection. In reality, the majority (70%-90%) of low-grade gliomas are detected by cranial MRI because of seizures. At this time, often patients do not have significant neurological symptoms and patients are reluctant to operate for fear of postoperative functional decline. The literature reports that low-grade gliomas progress to high-grade gliomas after a quiescent period of 4-5 years. Surgery on detection is twice as long as survival with observation followed by surgery. Both screening-detected and epilepsy-detected low-grade gliomas should be operated early to improve the prognosis. Most high-grade gliomas are found because of headache, limb movement, speech, and cognitive dysfunction. Whether the glioma is a high-grade glioma transformed from a low-grade or a primary high-grade glioma, the prognosis remains unsatisfactory after aggressive surgery and radiotherapy. Early screening and early surgery should be enhanced for gliomas. To improve the probability of clinical cure.